Inhibition of Anandamide Hydrolysis by Cyclohexyl Carbamic Acid 3′-Carbamoyl-3-yl Ester (URB597) Reverses Abuse-Related Behavioral and Neurochemical Effects of Nicotine in Rats
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Emerging evidence suggests that the rewarding, abuse-related effects of nicotine are modulated by the endocannabinoid system of the brain. For example, pharmacological blockade or genetic deletion of cannabinoid CB1 receptors can reduce or eliminate many abuse-related behavioral and neurochemical effects of nicotine. Furthermore, doses of Δ9-tetrahydrocannabinol and nicotine that are ineffective when given alone can induce conditioned place preference when given together. These previous studies have used systemically administered CB1 receptor agonists and antagonists and gene deletion techniques, which affect cannabinoid CB1 receptors throughout the brain. A more functionally selective way to alter endocannabinoid activity is to inhibit fatty acid amide hydrolase (FAAH), thereby magnifying and prolonging the effects of the endocannabinoid anandamide only when and where it is synthesized and released on demand. Here, we combined behavioral and neurochemical approaches to evaluate whether the FAAH inhibitor URB597 (cyclohexyl carbamic acid 3′-carbamoyl-3-yl ester) could alter the abuse-related effects of nicotine in rats. We found that URB597, at a dose (0.3 mg/kg) that had no behavioral effects by itself, prevented development of nicotine-induced conditioned place preference (CPP) and acquisition of nicotine self-administration. URB597 also reduced nicotine-induced reinstatement in both CPP and self-administration models of relapse. Furthermore, in vivo microdialysis showed that URB597 reduced nicotine-induced dopamine elevations in the nucleus accumbens shell, the terminal area of the brain's mesolimbic reward system. These findings suggest that FAAH inhibition can counteract the addictive properties of nicotine and that FAAH may serve as a new target for development of medications for treatment of tobacco dependence.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Picciotto, M. R., Zoli, M., Rimondini, R., Léna, C., Marubio, L. M., Pich, E. M., Fuxe, K., & Changeux, J.-P. (1998) · Nature · doi:10.1038/34413 · Cited by 1,320 · cited 1×
“First, AEA, protected from degradation by URB597, may directly inhibit 4/ 2 nicotinic acetylcholine receptors (Spivak et al., 2007; Butt et al., 2008), which are clearly implicated in the rewarding effects of nicotine (Picciotto et al., 1998; Maskos et al., 2005; Walters et al., 2006).”
BackgroundModulation of anxiety through blockade of anandamide hydrolysis
Kathuria, S., Gaetani, S., Fegley, D., Valiño, F., Duranti, A., Tontini, A., Mor, M., Tarzia, G., Rana, G. L., Calignano, A., et al. (2003) · Nature Medicine · doi:10.1038/nm803 · Cited by 1,293 · cited 5×
“…a selective inhibitor of FAAH, URB597, to magnify and prolong the effects of only one of the endocannabinoid signals, the AEA signal, when and where AEA is synthesized and released on demand in activated synapses (Kathuria et al., 2003; Fegley et al., 2005; Pertwee, 2005; Piomelli et al., 2006).”
BackgroundMethodInfluentialSelf-citationCB1 Cannabinoid Receptors and On-Demand Defense Against Excitotoxicity
Marsicano, G., Goodenough, S., Monory, K., Hermann, H., Eder, M., Cannich, A., Azad, S. C., Cascio, M. G., Gutiérrez, S. O., van der Stelt, M., et al. (2003) · Science · doi:10.1126/science.1088208 · Cited by 1,208 · cited 2×
“In addition, AEA is synthesized on demand and affects only a specific subgroup of cannabinoid CB1 receptors, i.e., those located in activated synapses (Marsicano et al., 2003; Pertwee, 2005; Di Marzo and Petrosino, 2007).”
BackgroundEffects of nicotine on the nucleus accumbens and similarity to those of addictive drugs.
Pontieri, F. E., Tanda, G., Orzi, F., & Chiara, G. D. (1996) · Nature · doi:10.1038/382255a0 · Cited by 1,073 · cited 2×
“…its ability to activate the mesolimbic dopaminergic system by enhancing firing rate and burst firing of dopaminergic neurons in the ventral tegmental area (VTA) (Mereu et al., 1987) and increasing dopamine release in terminal areas, especially in the nucleus accumbens shell (Pontieri et al., 1996).”
BackgroundSelf-citationCorrigall, W. A., Coen, K. M., & Adamson, K. L. (1994) · Brain Research · doi:10.1016/0006-8993(94)90401-4 · Cited by 740 · cited 1×
“The mesolimbic dopamine system plays a pivotal role in the development of nicotine addiction, and the VTA, in particular, is a critical brain area for nicotine’s rewarding effects (Corrigall et al., 1994).”
BackgroundNicotine reinforcement and cognition restored by targeted expression of nicotinic receptors
Maskos, U., Molles, B. E., Pons, S., Besson, M., Guiard, B. P., Guilloux, J.-P., Evrard, A., Cazala, P., Cormier, A., Mameli-Engvall, M., et al. (2005) · Nature · doi:10.1038/nature03694 · Cited by 566 · cited 2×
“, 2008), which are clearly implicated in the rewarding effects of nicotine (Picciotto et al., 1998; Maskos et al., 2005; Walters et al., 2006).”
BackgroundFegley, D., Gaetani, S., Duranti, A., Tontini, A., Mor, M., Tarzia, G., & Piomelli, D. (2005) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.078980 · Cited by 427
Self-citationCohen, C., Perrault, G., Voltz, C., Steinberg, R., & Soubrié, P. (2002) · Behavioural Pharmacology · doi:10.1097/00008877-200209000-00018 · Cited by 396 · cited 2×
“…of nicotine-induced CPP (Castané et al., 2002; Le Foll and Goldberg, 2004; Forget et al., 2005, Merritt et al., 2008), prevent relapse to nicotine-seeking behavior in rats (Shoaib, 2008), and prevent nicotine-induced dopamine elevations in the nucleus accumbens shell (Cohen et al., 2002).”
Walters, C. L., Brown, S., Changeux, J.-P., Martin, B., & Damaj, M. I. (2006) · Psychopharmacology · doi:10.1007/s00213-005-0295-x · Cited by 206 · cited 4×
“Animals that lack expression of the 2 subunit do not readily self-administer nicotine or express nicotine-induced CPP (Picciotto et al., 1999; Walters et al., 2006).”
BackgroundInfluential
Cited by
The endocannabinoid system and the brain.
Mechoulam, R., & Parker, L. A. (2013) · Annual Review of Psychology · doi:10.1146/annurev-psych-113011-143739 · Cited by 1,090
“FAAH inhibition has been selectively evaluated for prevention of nicotine seeking (Forget et al. 2009, Scherma et al. 2008).”
BackgroundMethodEndocannabinoid signalling in reward and addiction
Parsons, L. H., & Hurd, Y. L. (2015) · Nature Reviews Neuroscience · doi:10.1038/nrn4004 · Cited by 481
The dark side of emotion: the addiction perspective
Koob, G. F. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.11.044 · Cited by 433
“Equally compelling for the current thesis, there is some evidence that drug-seeking behavior can be blocked by endocannabinoid clearance inhibition (Scherma et al., 2008; Adamczyk et al., 2009; Forget et al., 2009).”
BackgroundAddiction and Stress: An Allostatic View
Koob, G. F., & Schulkin, J. (2019) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2018.09.008 · Cited by 315
Endocannabinoid-mediated synaptic plasticity and addiction-related behavior
Sidhpura, N., & Parsons, L. H. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.05.034 · Cited by 92
Metadata
- Authors
- Scherma, M., Panlilio, L. V., Fadda, P., Fattore, L., Gamaleddin, I., Le Foll, B., Justinová, Z., Mikics, E., Haller, J., Medalie, J., Stroik, J., Barnes, C., Yasar, S., Tanda, G., Piomelli, D., Fratta, W., & Goldberg, S. R.
- Venue
- The Journal of Pharmacology and Experimental Therapeutics
- Publisher
- Elsevier BV
- Published
- 2008-11
- Volume
- 327
- Issue
- 2
- Pages
- 482-490
- ISSN
- 0022-3565 (ISSN-L)
- OpenAlex
- W2104645663
- Cited by
- 138
- References
- 9
- FWCI
- 5.79
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Inhibition of Anandamide Hydrolysis by Cyclohexyl Carbamic Acid 3′-Carbamoyl-3-yl Ester (URB597) Reverses Abuse-Related Behavioral and Neurochemical Effects of Nicotine in Rats. https://app.cochat.ai/papers/10.1124/jpet.108.142224
- The paper
- Scherma, M., Panlilio, L. V., Fadda, P., Fattore, L., Gamaleddin, I., Le Foll, B., Justinová, Z., Mikics, E., Haller, J., Medalie, J., Stroik, J., Barnes, C., Yasar, S., Tanda, G., Piomelli, D., Fratta, W., & Goldberg, S. R. (2008). Inhibition of Anandamide Hydrolysis by Cyclohexyl Carbamic Acid 3′-Carbamoyl-3-yl Ester (URB597) Reverses Abuse-Related Behavioral and Neurochemical Effects of Nicotine in Rats. The Journal of Pharmacology and Experimental Therapeutics. https://doi.org/10.1124/jpet.108.142224
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.